Modalities, Maps and Margins: Optimizing Oncologic Efficacy
Mark Emberton, MD, FRCS, discusses current technologies and modern lesion management strategies for destroying prostate cancer cells.
Read MoreSelect Page
Posted by Mark Emberton, MD, FRCS | Mar 2023
Mark Emberton, MD, FRCS, discusses current technologies and modern lesion management strategies for destroying prostate cancer cells.
Read MorePosted by Cary (C.J.) Stimson, MD, JD | Mar 2023
Cary (C.J.) Stimson, MD, JD, discusses the potential of value care bundling to improve the healthcare landscape.
Read MorePosted by Edwin M. Posadas, MD, FACP | Mar 2023
E. David Crawford, MD, interviews Edwin M. Posadas, MD, FACP, on his clinical experience with lutetium.
Read MorePosted by Christopher P. Smith, MD, MBA, MSS | Mar 2023
Christopher P. Smith, MD, MBA, MSS, discusses management of overactive bladder (OAB), drawing on 20 years of clinical experience.
Read MorePosted by Sam S. Chang, MD, MBA | Mar 2023
Sam S. Chang, MD, MBA, discusses NMIBC guidelines, best practices, and controversies related to risk-stratification, surveillance, and treatment strategies.
Read More